Skip to main content

Table 1 Patient characteristics

From: Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases

Characteristics

Before PSM

After PSM

WBRT + SIB

(n = 82)

WBRT

(n = 83)

P value

WBRT + SIB

(n = 52)

WBRT

(n = 52)

P value

Age, median(range), years

60(27–78)

59 (34–80)

0.634

60 (27–74)

61 (34–80)

0.974

Sex

      

 Male

61 (74.4%)

44 (53.0%)

0.004*

32 (61.5%)

35 (67.3%)

0.539

 Female

21 (25.6%)

39 (47.0%)

 

20 (38.5%)

17 (32.7%)

 

KPS

      

 90–100

26 (31.7%)

28 (33.7%)

0.876

12 (23.1%)

16 (30.8%)

0.751

 70–80

54 (65.9%)

52 (62.7%)

 

39 (75.0%)

35 (67.3%)

 

  < 70

2 (2.4%)

3 (3.6%)

 

1 (1.9%)

1 (1.9%)

 

Primary tumour

      

 NSCLC

39 (47.6%)

40 (48.2%)

< 0.001*

28 (47.6%)

25 (48.2%)

0.675

 SCLC

35 (42.7%)

28 (33.7%)

 

20 (42.7%)

25 (33.7%)

 

 Breast cancer

1 (1.2%)

14 (16.9%)

 

1 (1.9%)

1 (1.9%)

 

 Other cancer

7 (8.5%)

1 (1.2%)

 

3 (5.8%)

1 (1.9%)

 

GPA

      

 3.0 ≤ GPA < 4.0

18 (22.0%)

10 (12.0%)

0.017*

3 (5.8%)

8 (15.4%)

0.251

 2.0 ≤ GPA < 3.0

39 (47.6%)

33 (39.8%)

 

18 (34.6%)

21 (40.4%)

 

 1.0 ≤ GPA < 2.0

22 (26.8%)

26 (31.3%)

 

24 (46.2%)

16 (30.8%)

 

 GPA < 1.0

3 (3.7%)

14 (16.9%)

 

7 (13.5%)

7 (13.5%)

 

Extracranial metastases

      

 Yes

30 (36.6%)

40 (48.2%)

0.132

21(40.4%)

20(38.5%)

0.841

 No

52 (63.4%)

43 (51.8%)

 

31 (59.6%)

32 (61.5%)

 

Extracranial disease

      

 Stable

57 (69.5%)

61 (73.5%)

0.571

34 (65.4%)

37 (71.2%)

0.527

 Active

25 (30.5%)

22 (26.5%)

 

18 (34.6%)

15 (28.8%)

 

Brain surgery before RT

      

 Yes

4 (4.9%)

3 (3.6%)

0.987

3 (5.8%)

2 (3.8%)

> 0.999

 No

78 (95.1%)

80 (96.4%)

 

49 (94.2%)

50 (96.2%)

 

Sum of longest diameters of BM, mean (range), cm

3.6 (0.6–11.0)

4.4 (1.0–15.3)

0.291

4.0 (0.6–11.0)

4.0 (1.0–12.8)

0.782

Targeted therapy

      

 Yes

16 (19.5%)

26 (31.3%)

0.082

13 (25.0%)

15 (28.8%)

0.658

 No

66 (80.5%)

57 (68.7%)

 

39 (75.0%)

37 (71.1%)

 

Immunotherapy

      

 Yes

8 (9.8%)

5 (6.0%)

0.374

6 (11.5%)

5(9.6%)

0.750

 No

74 (90.2%)

78 (94.0%)

 

46 (88.5%)

47 (90.4%)

 

Meningeal metastasis

      

 Yes

5 (6.1%)

2 (2.4%)

0.430

3 (5.8%)

0 (0.0%)

0.241

 No

77 (93.9%)

81 (97.6%)

 

49 (94.2%)

52 (100.0%)

 

Salvage therapy†

      

 Yes

6 (7.3%)

13 (15.7%)

0.093

5 (9.6%)

10 (19.2%)

0.163

 No

76 (92.7%)

70 (84.3%)

 

47 (90.4%)

42 (80.8%)

 
  1. Abbreviations: PSM propensity score matching, WBRT whole-brain radiation therapy, SIB simultaneous integrated boost, KPS Karnofsky Performance Status, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, GPA graded prognostic assessment, RT radiotherapy, BM brain metastasis. *P < 0.05. †Salvage therapy refers to patients undergoing further brain radiation or brain surgery following the progression of brain tumours
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us